structur
analogu
nucleosid
nucleosid
analogu
na
use
treatment
cancer
viral
infect
antivir
na
inhibit
replic
viral
genom
wherea
anticanc
na
inhibit
cellular
dna
replic
repair
na
inact
prodrug
depend
intracellular
phosphoryl
pharmacolog
activ
triphosph
form
deoxyribonucleosid
kinas
dnk
ribonucleosid
kinas
rnk
catalyz
first
phosphoryl
step
convert
deoxyribonucleosid
ribonucleosid
correspond
monophosph
form
dnk
studi
intens
wherea
rnk
thoroughli
investig
overview
focus
substrat
specif
tissu
distribut
subcellular
locat
mammalian
dnk
rnk
role
activ
na
deoxyribonucleotid
ribonucleotid
build
block
dna
rna
respect
nucleotid
built
nitrogen
ringstructur
base
pentos
sugar
deoxyribos
ribos
phosphat
group
dna
replic
enzym
known
dna
polymeras
human
dna
polymeras
h
q
locat
cell
nucleu
enzym
replic
repair
nuclear
dna
zannishadjppoulu
price
hubscher
et
al
mitochondri
dna
mtdna
replic
catalyz
dna
polymeras
g
taanman
enzym
use
singlestrand
dna
templat
catalyz
synthesi
complementari
strand
deoxyribonucleosid
triphosph
datp
dctp
dgtp
dttp
nucleotid
ad
free
oh
group
basepair
polynucleotid
dna
chain
extend
fig
accuraci
dna
replic
fundament
genet
stabil
cell
bacteria
higher
eukaryot
error
frequenc
rang
per
base
replic
timsit
kunkel
bebenek
although
error
dna
synthesi
play
role
age
diseas
like
cancer
spontan
mutat
also
provid
opportun
genet
variat
primari
basi
evolut
high
fidel
dna
replic
requir
maintain
mammalian
genom
bp
depend
balanc
suppli
deoxyribonucleotid
reichard
inhibit
deoxyribonucleotid
synthesi
result
mutagen
chang
cell
growth
arrest
cell
death
two
exampl
compound
interfer
synthesi
deoxyribonucleotid
hydroxyurea
inhibit
ribonucleotid
reductas
rr
methotrex
inhibit
dihydrofol
reductas
thymidyl
synthas
ts
also
purin
nucleotid
de
novo
pathway
fig
inhibit
enzym
result
deoxyribonucleotid
pool
imbal
thu
impair
dna
replic
anoth
way
interfer
dna
synthesi
structur
modifi
nucleosid
ie
nucleosid
analogu
na
na
lack
oh
group
incorpor
dna
act
chain
termin
new
deoxyribonucleotid
attach
grow
dna
strand
fig
na
intact
oh
group
absolut
chain
termin
evid
incorpor
dna
sever
impair
chain
elong
tan
et
al
deoxyribonucleotid
ribonucleotid
synthes
within
cell
carrier
protein
cell
membran
neg
charg
phosphat
group
prevent
diffus
across
membran
pathway
deoxyribonucleotid
ribonucleotid
synthesi
call
de
novo
pathway
salvag
pathway
fig
reichard
via
de
novo
ribonucleotid
pathway
ribonucleotid
synthes
small
molecul
eg
amino
acid
phosphat
co
ribonucleosid
monophosph
phosphoryl
fig
oh
group
ribonucleosid
diphosph
also
reduc
correspond
deoxyribonucleosid
diphosph
via
de
novo
deoxyribonucleotid
pathway
irrevers
reaction
catalyz
rr
reichard
greenberg
hilfing
burton
et
al
prolifer
cell
de
novo
deoxyribonucleotid
synthesi
main
sourc
nuclear
dna
replic
wright
et
al
deoxyribonucleotid
synthes
salvag
pathway
believ
import
dna
repair
xu
et
al
salvag
deoxyribonucleotid
pathway
deriv
deoxyribonucleosid
catalyz
deoxyribonucleosid
kinas
dnk
nucleosid
monophosph
kinas
nmpk
nucleosid
diphosph
kinas
ndpk
fig
addit
salvag
pathway
ribonucleotid
first
free
base
phosphoryl
direct
sugar
phosphat
transfer
second
salvag
ribonucleotid
pathway
ribonucleosid
phosphoryl
triphosph
form
fig
b
kornberg
baker
ribonucleosid
deoxyribonucleosid
import
cell
nucleosid
transport
protein
facilit
diffus
activ
transport
nucleosid
across
membran
phosphoryl
ribonucleosid
ribonucleosid
monophosph
catalyz
ribonucleosid
kinas
rnk
phosphoryl
reaction
deoxyribonucleosid
catalyz
dnk
fig
dnk
rnk
phosphoryl
reaction
irrevers
howev
monophosph
dephosphoryl
nucleosid
nt
reichard
rampazzo
et
al
convers
ribonucleosid
monophosph
deoxyribonucleosid
monophosph
triphosph
form
occur
subsequ
revers
phosphotransferas
reaction
catalyz
nmpk
ndpk
group
nmpk
human
cell
dtmp
kinas
dtmpk
umpcmp
kinas
umpcmpk
isozym
adenyl
kinas
ak
sever
guanyl
kinas
guk
van
rompay
et
al
human
ndpk
famili
compris
least
isozym
lacomb
et
al
interest
enzym
involv
activ
na
na
phosphoryl
via
ribonucleotid
deoxyribonucleotid
salvag
pathway
correspond
triphosph
initi
phosphoryl
step
dnk
case
ratelimit
step
format
dntp
natp
studi
care
johansson
eriksson
johansson
et
al
tan
et
al
galmarini
et
al
galmarini
et
al
howev
less
known
rnk
focu
review
reconstitut
metabol
pathway
activ
character
phosphoryl
step
import
develop
ration
use
compound
antivir
anticanc
therapi
deoxyribonucleosid
ribonucleosid
import
cell
nucleosid
transport
deoxyribonucleosidesribonucleosid
phosphoryl
triphosph
form
subsequ
phosphoryl
step
catalyz
dnksrnk
nmpk
ndpk
human
cell
dnk
thymidin
kinas
thymidin
kinas
deoxycytidin
kinas
dck
deoxyguanosin
kinas
dgk
bohman
eriksson
et
al
nomenclatur
dnk
base
prefer
substrat
enzym
also
accept
substrat
tabl
phosphoryl
dthd
durd
munchpetersen
et
al
abl
use
phosphat
donor
atp
show
highest
effici
ellim
van
der
weyden
pyrimidin
dnk
phosphoryl
dthd
durd
dcyd
munchpetersen
et
al
addit
dcyd
dck
phosphoryl
dado
dguo
sarup
friland
usova
eriksson
enzym
use
sever
nucleotid
phosphat
donor
utp
suggest
import
phosphat
donor
white
hine
turk
et
al
dgk
phosphoryl
dguo
dado
dino
gower
et
al
wang
et
al
dgk
use
sever
phosphat
donor
vitro
utp
prefer
phosphat
donor
zhu
et
al
known
rnk
human
cell
adenosin
kinas
adk
uridinecytidin
kinas
uridinecytidin
kinas
spychala
et
al
van
rompay
et
al
exist
human
guanosin
kinas
far
report
adk
catalyz
phosphoryl
ado
amp
tabl
spychala
et
al
adk
also
implic
phosphoryl
dado
vivo
ullman
et
al
although
purifi
adk
higher
k
dado
ado
hurley
et
al
studi
adkdefici
cell
line
demonstr
account
signific
part
total
dado
phosphoryl
lymphoblastoid
cell
line
carson
et
al
ullman
et
al
adk
might
play
major
role
phosphoryl
dado
higher
concentr
wherea
dck
play
critic
role
low
concentr
verhoef
et
al
hershfield
et
al
atp
gtp
shown
effect
phosphat
donor
adk
yamada
et
al
adk
feedback
regul
product
amp
adp
palella
et
al
uck
catalyz
phosphoryl
urd
cyd
ump
cmp
tabl
enzym
first
observ
canellaki
mammalian
liver
reichard
ehrlich
ascit
tumor
shown
present
rapidli
prolifer
tissu
reichard
purif
properti
tissuepurifi
uck
review
anderson
cihak
rada
traut
jone
differ
investig
observ
multipl
enzym
peak
band
chromatographi
isoelectr
focus
electrophoresi
krystal
webb
krystal
scholefield
fulchignonilataud
et
al
greenberg
et
al
ahm
welch
absil
et
al
ahm
baker
dubinina
et
al
fulchignonilataud
roux
recent
human
uck
name
clone
koi
anderson
brockman
orengo
van
rompay
two
mode
regul
shown
uck
feedback
regul
end
product
ctp
utp
exhibit
competit
inhibit
respect
phosphat
donor
anderson
brockman
orengo
payn
traut
regul
chang
quaternari
structur
caus
orthophosph
atp
ctp
payn
traut
ropp
traut
atp
stabil
enzym
activ
tetramer
form
wherea
utp
ctp
dissoci
enzym
inact
monom
payn
traut
cheng
et
al
cdna
human
dnk
clone
bradshaw
chottin
et
al
align
predict
amino
acid
sequenc
sequenc
dck
dgk
show
c
ident
fig
relat
tk
escherichia
coli
poxvirus
show
littl
sequenc
similar
dnk
gentri
eriksson
wang
like
human
dnk
origin
common
progenitor
kinas
propos
first
gene
duplic
gener
progenitor
kinas
progenitor
dckdgklike
kinas
knecht
et
al
date
crystal
structur
determin
dgk
recent
dck
sabini
et
al
dck
dgk
code
region
distribut
exon
respect
fig
three
cdna
human
rnk
also
clone
human
tissu
differ
isoform
human
adk
clone
sequenc
spychala
et
al
mcnalli
et
al
isoform
similar
biochem
function
properti
sequenc
variat
first
encod
residu
short
form
replac
residu
long
form
mcnalli
et
al
mrna
form
postul
aris
singl
adk
gene
differenti
splice
spychala
et
al
mcnalli
et
al
far
signific
form
elucid
adk
show
littl
sequenc
similar
mammalian
rnk
contrast
region
identifi
signific
sequenc
ident
microbi
ribokinas
fructokinas
bacteri
inosineguanosin
kinas
spychala
et
al
mathew
et
al
adk
group
carbohydr
purin
kinas
pfkb
famili
crystal
structur
adk
recent
solv
human
adk
mathew
et
al
well
toxoplasma
gondii
adk
cook
et
al
schumach
et
al
structureact
relationship
examin
chines
hamster
adk
make
systemat
delet
ntermin
ctermin
end
maj
et
al
human
adk
code
region
distribut
exon
fig
longest
open
read
frame
encod
acid
protein
predict
mass
kda
consist
amino
acid
predict
mass
kda
human
similar
amino
acid
sequenc
enzym
c
c
similar
uck
caenorhabd
elegan
e
coli
respect
fig
human
code
region
distribut
exon
fig
human
dnk
human
gene
local
chromosom
kuo
et
al
petti
et
al
chromosom
dck
chromosom
stegmann
et
al
dgk
chromosom
rnk
human
adk
gene
assign
region
klobutch
et
al
franck
thompson
human
gene
gene
local
chromosom
respect
van
rompay
et
al
cytosol
enzym
mitochondri
enzym
ntermin
mitochondri
import
signal
fig
tabl
kit
leung
lee
cheng
wettin
et
al
wang
eriksson
fig
green
fluoresc
protein
gfp
show
mainli
cytosol
fluoresc
fluoresc
border
outlin
cell
membran
human
like
altern
splice
cdna
isoform
human
lack
ntermin
mitochondri
target
sequenc
mitochondri
locat
support
fact
fulllength
mous
mitochondri
locat
wettin
et
al
wang
eriksson
mtdna
deplet
syndrom
md
link
mutat
dgk
mancuso
et
al
recombin
dck
nuclear
import
signal
dck
fuse
gfp
locat
nucleu
wherea
nativ
dck
report
locat
cytosol
hatzi
et
al
import
transport
dck
subcellular
compart
remain
unclear
ntermin
sequenc
dgk
contain
mitochondri
import
signal
enzym
locat
mitochondri
matrix
gower
et
al
eriksson
surprisingli
dgk
might
reloc
cytosol
compart
apoptosi
eriksson
adk
report
cytosol
enzym
tabl
andr
fox
uck
activ
howev
detect
nuclear
cytosol
microsom
fraction
differ
investig
cell
tissu
durham
ive
cihak
rada
greenberg
et
al
express
fusion
gfp
show
predominantli
locat
nucleu
wherea
locat
cytosol
fig
tabl
van
rompay
relev
find
probabl
minim
nuclear
membran
allow
diffus
small
protein
nucleotid
cytosol
nucleu
express
regul
throughout
cell
cycl
transcript
translat
posttransl
regulatori
mechan
mrna
protein
rise
near
g
boundari
peak
earli
phase
declin
g
phase
sherley
kelli
et
al
kim
et
al
reason
meticul
control
fulli
elucid
sever
regulatori
mechan
propos
invert
ccaat
motif
promot
respons
transcript
activ
gene
posttranscript
posttransl
mechan
halflif
mrna
protein
regul
activ
acid
sequenc
carboxyl
terminu
specif
degrad
mitosi
fig
human
deoxyribonucleosid
ribonucleosid
gene
famili
human
dgk
dck
adk
gene
structur
genom
sequenc
deriv
dna
fragment
chromosom
nt
code
region
distribut
exon
b
genom
sequenc
deriv
dna
fragment
chromosom
nt
code
region
distribut
exon
c
dck
nm
genom
sequenc
deriv
dna
fragment
chromosom
nt
code
region
distribut
exon
dgk
nm
genom
sequenc
deriv
dna
fragment
chromosom
nt
code
region
distribut
exon
e
adk
genom
sequenc
deriv
dna
fragment
chromosom
nt
code
region
distribut
exon
f
genom
sequenc
deriv
dna
fragment
chromosom
nt
code
region
distribut
exon
g
genom
sequenc
deriv
dna
fragment
chromosom
nt
code
region
distribut
exon
extent
phosphoryl
serin
residu
protein
enzymat
level
atpdepend
revers
shift
low
high
affin
form
phasedepend
mechan
transcript
factor
complex
sever
factor
munchpetersen
et
al
dck
dgk
express
throughout
cell
cycl
repres
rather
small
fraction
cellular
tk
level
compar
activ
prolifer
cell
howev
correspond
predomin
fraction
tk
activ
rest
termin
differenti
cell
activ
virtual
undetect
activ
tissu
extract
appear
proport
cellular
mitochondri
content
rather
growth
state
cell
et
al
purifi
mani
tissu
spleen
liver
heart
brain
jansson
et
al
northern
blot
analys
show
mrna
speci
ubiquit
express
wang
et
al
highest
level
liver
pancrea
muscl
brain
dck
seem
cell
cycl
regul
richel
et
al
dck
express
low
level
tissu
high
level
present
lymphoid
tissu
particularli
high
level
immatur
tlymphoblast
et
al
northern
blot
analysi
show
dck
mrna
highest
level
thymu
skelet
muscl
fetal
liver
bone
marrow
brain
liver
brain
report
low
dck
activ
spasokukotskaja
et
al
molecular
mechan
regul
tissuespecif
express
dck
yet
clear
dgk
constitut
express
throughout
cell
cycl
enzym
level
believ
proport
amount
mitochondria
tissu
northern
blot
analysi
dgk
mrna
suggest
dgk
express
tissu
highest
level
muscl
brain
liver
lymphoid
tissu
adk
play
key
role
regul
intracellular
extracellular
level
adenosin
manfredi
holm
bern
adenosin
widespread
effect
cardiovascular
nerv
respiratori
immun
system
fox
kelley
manfredi
holm
inhibitor
adk
might
play
import
pharmacolog
role
increas
intravascular
adenosin
concentr
act
antiinflammatori
agent
cronstein
firestein
et
al
northern
blot
analysi
adk
correspond
mrna
speci
kb
detect
tissu
placenta
liver
muscl
kidney
heart
pancrea
brain
lung
investig
spychala
et
al
uck
activ
demonstr
close
correl
cell
prolifer
weichsel
et
al
uck
wide
distribut
purifi
mammalian
liver
lung
brain
heart
kidney
pancrea
spleen
thymu
bone
marrow
testi
skelet
muscl
small
intestin
herzfeld
raper
shen
et
al
mous
mrna
previous
shown
express
brain
tissu
ropp
traut
human
mrna
human
testi
ozaki
et
al
recent
demonstr
human
mrna
detect
isoform
c
c
kb
sever
tissu
c
band
ubiquit
express
investig
tissu
high
level
express
liver
kidney
skelet
muscl
heart
wherea
low
level
present
brain
placenta
small
intestin
spleen
band
c
kb
detect
skelet
muscl
heart
liver
kidney
human
mrna
detect
placenta
transcript
c
c
kb
testi
blot
northern
blot
van
rompay
et
al
molecular
mechan
regul
tissuespecif
express
andor
yet
clear
na
use
clinic
treatment
certain
viral
infect
tumor
tabl
recent
current
knowledg
concern
molecular
mechan
activ
resist
major
na
cancer
treatment
review
galmarini
et
al
galmarini
et
al
anticanc
deoxyribonucleosid
analogu
use
clinic
includ
cladribin
cda
fludarabin
faraa
cytarabin
arac
gemcitabin
dfdc
na
didanosin
ddi
dideoxycytidin
zalcitabin
ddc
lamivudin
dideoxythymidin
zidovudin
azt
deoxythymidin
stavudin
abacavir
abc
use
antivir
treatment
combin
therapi
compris
least
antihiv
drug
becom
standard
treatment
aid
hivinfect
patient
compound
current
use
advanc
clinic
trial
belong
one
follow
class
nucleosid
revers
transcriptas
rt
inhibitor
nrti
ie
azt
ddi
ddc
abc
nucleotid
rt
inhibitor
ntrti
tenofovir
pmpa
nonnrti
nnrti
ie
nevirapin
delavirdin
efavirenz
emivirin
proteas
inhibitor
pi
ie
saquinavir
ritonavir
indinavir
nelfinavir
amprenavir
lopinavir
de
clercq
recent
new
develop
antihiv
chemotherapi
review
tan
et
al
de
clercq
address
current
use
nrti
antivir
na
also
anticanc
na
major
problem
treatment
cancer
viral
diseas
na
acquir
resist
side
effect
delay
cytotox
accord
galmarini
et
al
gener
mechan
resist
na
describ
cell
line
clinic
sampl
insuffici
intracellular
concentr
natp
might
due
ineffici
cellular
uptak
decreas
level
activ
enzym
increas
catabol
elev
level
nt
deaminas
expans
dntp
pool
inabl
achiev
suffici
alter
dna
strand
dntp
pool
might
result
alter
interact
dna
polymeras
lack
inhibit
rr
inadequ
exonucleas
activ
defect
induct
apoptosi
zhu
review
induct
apoptosi
na
key
event
apoptosi
caspas
activ
may
consequ
death
receptor
trigger
mitochondri
activ
possibl
yet
defin
initi
event
thu
cell
death
pathway
may
initi
differ
subcellular
compart
includ
plasma
membran
cytosol
mitochondria
nucleu
major
strategi
fight
cancer
induc
apoptosi
incorpor
na
nuclear
dna
caus
dna
strand
break
sphase
cell
regard
crucial
initi
apoptosi
howev
also
pathway
report
induc
apoptosi
mechan
link
dna
damag
induc
na
apoptosi
particularli
mitochondria
larg
unknown
studi
suggest
mitochondria
may
involv
induct
apoptosi
na
novel
strategi
select
target
mitochondri
permeabil
agent
malign
cell
zhu
solari
et
al
na
phosphoryl
triphosph
form
incorpor
cellular
viral
dna
cellular
viral
dna
polymeras
rna
polymeras
viral
rt
fig
presenc
na
dna
caus
termin
dna
elong
often
also
resist
proofread
exonucleas
mechan
anticanc
antivir
activ
na
may
ultim
note
compound
distinct
metabol
pharmacolog
properti
analogu
also
inhibit
key
enzym
eg
rr
ts
dcmp
deaminas
involv
gener
purin
pyrimidin
nucleotid
rna
synthesi
directli
activ
caspas
cascad
effect
may
lead
cell
death
galmarini
et
al
sever
studi
provid
evid
dutp
pyrophosphatas
dutpas
vital
cellular
case
viral
dna
replic
fig
ladner
payn
elder
aberr
dutp
metabol
play
critic
role
molecular
mechan
cell
kill
induc
inhibitor
dihydrofol
reductas
ts
normal
condit
uracil
preclud
dna
combin
action
dutpas
uracildna
glycosylas
udg
howev
ts
inhibit
dutp
pool
may
accumul
overwhelm
dutpas
result
repeat
cycl
uracil
misincorpor
detriment
repair
lead
strand
break
cell
death
furthermor
herpesvirus
type
poxvirus
nonprim
retrovirus
eiav
visna
caev
fiv
encod
dutpas
wherea
primat
retrovirus
hiv
siv
studebak
et
al
fleischmann
et
al
studi
sever
viru
model
suggest
viral
dutpas
may
requir
viru
replic
rest
cell
wherea
prolifer
cell
cellular
dutpas
may
substitut
mutant
viral
protein
fleischmann
et
al
cellular
viral
dutpas
may
suitabl
target
anticanc
antivir
therapi
accumul
pharmacolog
activ
natp
howev
counteract
dephosphoryl
na
nt
degrad
na
enzym
involv
nucleosid
nucleotid
catabol
human
dnk
dck
dgk
catalyz
initi
often
ratelimit
phosphoryl
step
investig
detail
johansson
et
al
dck
studi
intens
year
enzym
respons
initi
activ
number
clinic
import
anticanc
antivir
drug
arac
faraa
cda
dfdc
ddc
fig
bohman
eriksson
johansson
karlsson
impair
dck
express
activ
cell
result
resist
drug
indic
dck
play
key
role
metabol
pharmacolog
activ
verhoef
et
al
ullman
et
al
owen
et
al
ruiz
van
haperen
et
al
dumontet
et
al
et
al
also
shown
sensit
dckactiv
na
increas
overexpress
dck
dckdefici
tumor
cell
line
hapk
et
al
moreov
vitro
model
shown
crossresist
among
cda
dfdc
faraa
arac
reduc
dck
activ
underli
determin
resist
dumontet
et
al
arac
structur
analogu
dcyd
extens
use
treatment
acut
leukemia
lymphoma
fig
tabl
intracellular
penetr
arac
happen
carrier
protein
pumpmedi
transport
wiley
et
al
capizzi
et
al
insid
cell
arac
phosphoryl
dck
pyrimidin
nucleosid
kinas
activ
deriv
aractp
kufe
et
al
van
rompay
et
al
arac
cytotox
believ
result
combin
dna
polymeras
inhibit
incorpor
aractp
dna
competit
dctp
incorpor
caus
chain
termin
result
block
dna
synthesi
kufe
et
al
sustain
high
cellular
concentr
aractp
rel
dctp
thought
favor
drug
incorpor
replic
dna
therebi
initi
leukem
cell
death
associ
therapeut
respons
cytotox
activ
arac
limit
characterist
metabol
deamin
low
affin
dck
rapid
elimin
triphosph
deriv
cytostat
agent
dfdc
approv
treatment
pancreat
breast
nonsmal
cell
lung
cancer
fig
tabl
nobl
goa
phosphoryl
monophosph
cellular
dck
diphosph
form
umpcmpk
triphosph
form
ndpk
heinemann
et
al
plunkett
et
al
van
rompay
et
al
dfdcmp
inhibit
deoxycytidyl
deaminas
dfdcdp
inhibit
rr
dfdctp
inhibit
dna
synthesi
competit
inhibit
dna
polymeras
incorpor
replic
dna
heinemann
et
al
metabolit
incorpor
dna
chain
elong
termin
addit
anoth
nucleotid
dfdc
termin
dna
replic
effect
arac
dfdcmp
incorpor
difficult
cell
excis
dna
aracmp
ruiz
van
haperen
et
al
reason
dfdc
arac
activ
solid
tumor
might
multifactori
includ
differ
togeth
greater
lipophi
liciti
mask
chain
termin
rna
incorpor
rr
inhibit
observ
arac
cda
use
treatment
lymphoprolif
disord
hairi
cell
leukemia
chronic
lymphocyt
leukemia
cll
well
therapi
multipl
sclerosi
autoimmun
disord
fig
tabl
beutler
et
al
efficaci
howev
compromis
emerg
resist
cell
knowledg
mechan
cda
cytotox
limit
studi
focus
activ
andor
deactiv
drug
carson
et
al
among
propos
mechan
action
cda
incorpor
analogu
dna
inhibit
rr
inhibit
dna
repair
dna
strand
break
accumul
activ
poli
adpribos
polymeras
plunkett
gandhi
cda
also
shown
caus
direct
alter
mitochondri
function
might
trigger
apoptosi
disrupt
integr
mitochondria
lead
releas
proapoptot
mitochondri
protein
cytochrom
c
recent
studi
gener
cell
line
resist
cda
differ
level
initi
phosphoryl
enzym
dckdgk
chandra
et
al
cell
line
lower
dck
enzym
activ
heighten
dgk
activ
consequ
resist
cell
line
accumul
differ
level
phosphoryl
drug
cdatp
intracellularli
mechan
resist
cda
sole
correl
cdatp
accumul
also
may
dictat
chang
ca
sensit
mitochondri
event
chandra
et
al
cafda
clofarabin
new
cda
fig
tabl
use
phase
clinic
trial
encourag
preliminari
result
waud
et
al
phase
ii
clinic
trial
pediatr
refractoryrelaps
acut
myeloid
lymphoblast
leukemia
finish
kantarjian
et
al
human
leukemia
cell
line
cafda
effici
substrat
dck
activ
form
stabl
due
higher
phosphoryl
longer
retent
time
compar
cda
mechan
lead
acquir
resist
cafda
seem
similar
cda
lotfi
et
al
et
al
faraa
structur
analogu
ado
use
treatment
cll
fig
tabl
keat
therapeut
result
advanc
cll
still
unsatisfactori
term
complet
remiss
achiev
durat
spite
extens
use
purin
analogu
johnson
et
al
standard
therapi
remain
alkyl
agent
chlorambucil
rai
et
al
recent
combin
faraa
chlorambucil
emerg
approach
unfortun
might
coincid
significantli
higher
incid
major
infect
higher
healthcar
cost
rai
et
al
faraa
administ
faraamp
make
water
solubl
rapidli
dephosphoryl
serum
phosphatas
membranebound
nt
faraa
transport
insid
cell
via
carrier
protein
like
na
requir
phosphoryl
triphosph
form
faraatp
cytotox
activ
plunkett
saunder
faraa
like
cda
cytotox
divid
rest
cell
divid
cell
compound
inhibit
dna
synthesi
rr
consequ
reduc
pool
dntp
requir
dna
synthesi
enhanc
cytotox
selfpotenti
plunkett
et
al
enzym
target
faraa
includ
dna
primas
dna
polymeras
dna
ligas
dna
topoisomeras
ii
tseng
et
al
thu
mechan
action
faraa
prolifer
cell
mainli
cell
cycl
specif
incorpor
faraa
dna
phase
requir
induct
apoptosi
consoli
et
al
galmarini
et
al
galmarini
et
al
nondivid
cell
inhibit
cellular
dna
repair
like
explan
cytotox
faraa
cda
incorpor
faraatp
cdatp
dna
repair
mechan
lead
progress
accumul
dna
singlestrand
break
eventu
respons
apoptosi
pathway
sandov
et
al
anoth
consequ
treatment
direct
activ
pathway
faraatp
cdatp
nucleotid
activ
genini
et
al
moreov
faraa
cda
also
alter
gene
transcript
result
deplet
protein
requir
cell
surviv
incorpor
faraamp
rna
result
prematur
termin
rna
transcript
impair
function
templat
protein
synthesi
faraatp
inhibit
rna
synthesi
suppress
activ
rna
polymeras
ii
huang
et
al
hand
incorpor
cda
metabolit
present
one
dna
strand
reduc
yield
fulllength
transcript
hentosh
tibudan
conclus
inhibit
dna
repair
termin
mrna
transcript
consequ
deplet
protein
requir
cell
surviv
well
capac
faraatp
activ
apoptot
pathway
appear
contribut
cytotox
faraa
nondivid
cell
among
aid
drug
approv
food
drug
administr
fda
clinic
use
modifi
cytosin
analogu
ddc
fig
tabl
similar
dideoxynucleosid
analogu
metabol
activ
triphosph
form
incorpor
dna
hivrt
result
dna
chain
termin
ultim
cessat
viral
replic
fdaapprov
na
contain
unnatur
hlnucleosid
conform
shown
potent
less
toxic
disom
chang
et
al
mechanist
basi
sterochem
select
differ
toxic
isomer
ddc
compound
complet
understood
anderson
enzym
respons
format
dck
chang
et
al
incorpor
provir
dna
hivrt
thu
act
chain
termin
also
incorpor
cellular
dna
chain
polymeras
g
howev
polymeras
g
retain
activ
abl
excis
end
chain
may
explain
low
mitochondri
toxic
gray
et
al
neither
intracellularli
deamin
degrad
via
phosphorolyt
cleavag
pyrimidin
nucleosid
phosphorylas
coat
et
al
show
signific
antihiv
activ
less
toxic
azt
aztresist
hiv
strain
crossresist
soudeyn
et
al
ftc
thiacytidin
emtricitabin
phase
iii
trial
hiv
phase
iii
trial
hepat
b
viru
hbv
consid
use
multidrug
combin
therapi
hiv
hbv
infect
de
clercq
ftctp
competit
inhibitor
hivrt
ftcmp
may
incorpor
provir
dna
chain
termin
schinazi
et
al
ddc
show
potent
select
antihiv
activ
human
cell
variou
cell
line
ddc
phosphoryl
intracellularli
ddcmp
ddcdp
ddctp
concentr
order
magnitud
cooney
et
al
affin
ddctp
dna
polymeras
poor
intermedi
polymeras
h
high
polymeras
g
starn
cheng
compar
fdaapprov
antivir
na
ddc
highest
potenc
inhibit
mtdna
synthesi
chen
et
al
dgk
becom
interest
enzym
phosphoryl
number
clinic
import
anticanc
drug
cda
nelarabin
arag
difluorodeoxyguanosin
dfdg
wang
et
al
sjoberg
et
al
zhu
et
al
show
vitro
dgk
import
arag
dfdg
phosphoryl
wherea
dck
import
enzym
activ
cda
dfdc
zhu
et
al
overexpress
dgk
pancreat
cancer
cell
line
increas
sensit
purin
na
arag
dfdg
cda
zhu
et
al
cda
arag
dfdg
effici
phosphoryl
mitochondri
dgk
wang
et
al
zhu
et
al
zhu
et
al
zhu
et
al
earli
effect
mitochondri
function
hentosh
tibudan
zhu
et
al
howev
clear
relationship
cell
death
mtdna
incorpor
anticanc
na
sever
clinic
use
antivir
na
report
incorpor
mitochondria
dna
therebi
caus
sever
side
effect
lewi
dalaka
agarw
olivero
baril
et
al
chariot
et
al
effect
relat
mtdna
incorpor
describ
delay
effect
occur
sever
week
month
drug
exposur
lewi
et
al
dalaka
role
mitochondri
enzym
mitochondri
toxic
differ
mechan
behind
delay
acut
toxic
na
yet
clear
moyl
prodrug
biolog
activ
arag
proven
effici
especi
treatment
patient
tcell
acut
lymphoblast
leukemia
fig
tabl
aguayo
et
al
arag
substrat
dgk
dck
low
substrat
concentr
dgk
seem
prefer
enzym
zhu
et
al
rodriguez
et
al
although
mechan
arag
fulli
understood
accumul
aragtp
correl
cytotox
vitro
vivo
scharenberg
et
al
phosphoryl
triphosph
deriv
aragtp
act
structur
analogu
dgtp
therebi
incorpor
dna
demonstr
accumul
aragtp
independ
cell
cycl
surpris
dgk
dck
express
throughout
cell
cycl
furthermor
suggest
arag
exert
cytotox
action
induc
apoptosi
incorpor
aragmp
nuclear
dna
critic
event
trigger
apoptosi
rodriguez
gandhi
data
confirm
leukemia
cell
line
result
suggest
resist
apoptosi
aragresist
cell
might
contribut
overal
insensit
varieti
anticanc
drug
recent
studi
also
suggest
role
mitochondria
cellspecif
toxic
dgtp
intramitochondri
accumul
dgtp
inhibit
mtdna
arpaia
et
al
shown
arag
incorpor
mtdna
present
know
extent
mitochondri
incorpor
contribut
cytotox
action
analogu
also
shown
acut
cytotox
arag
caus
mtdna
damag
curbo
howev
exclud
longterm
exposur
arag
may
caus
mtdna
alter
subsequ
delay
mitochondri
toxic
sever
vitro
studi
perform
molecular
mechan
resist
arag
partli
conflict
result
recent
report
arag
resist
occur
separ
sequenti
mechan
first
mechan
associ
decreas
arag
incorpor
mtdna
second
event
associ
loss
dck
activ
loss
dgk
activ
recent
result
indic
mutat
gene
encod
dgk
associ
mtdna
deplet
saada
et
al
howev
could
demonstr
arag
caus
mtdna
deplet
alter
translat
mtdna
encod
gene
curbo
conclus
studi
necessari
enlighten
mani
molecular
mechan
associ
arag
resist
phosphoryl
pyrimidin
analogu
azt
fialuridin
fiau
fig
tabl
furman
et
al
munchpetersen
et
al
ahluwalia
et
al
introduct
azt
clinic
practic
usher
therapeut
era
aid
epidem
azt
thymidin
analogu
mainli
phosphoryl
howev
suggest
import
activ
azt
nondivid
cell
lack
et
al
follow
aztmp
entri
mitochondria
mechan
mitochondri
cytotox
possibl
studi
suggest
hypothesi
mitochondri
toxic
follow
phosphoryl
azttp
dna
polymeras
g
inhibit
either
azttp
serv
competit
substrat
incorpor
mtdna
termin
mtdna
chain
noncompetit
lewi
dalaka
howev
studi
conclud
azttp
respons
mitochondri
toxic
effect
observ
chronic
administr
szebeni
et
al
secondli
aztmp
altern
substrat
inhibitor
dtmp
dtmpk
furman
et
al
lavi
et
al
may
result
decreas
dttp
mitochondria
thu
decreas
mtdna
synthesi
et
al
lavi
et
al
conclus
although
mechan
azt
caus
mitochondri
toxic
requir
full
elucid
recent
evid
provid
aztmp
primarili
respons
toxic
anabolit
mainli
form
cytosol
sale
et
al
thymidyl
acid
mono
dodecylthio
ester
sodium
salt
fzd
fozivudin
tidoxil
belong
newer
azt
gener
drug
thioether
lipid
azt
conjug
recent
pass
phase
ii
clinic
trial
intracellularli
fzd
split
lipid
moieti
aztmp
latter
subsequ
phosphoryl
activ
metabolit
azttp
fzd
appear
effect
potenti
better
toler
azt
advantag
daili
intak
girard
et
al
like
azt
antihiv
drug
phosphoryl
ratelimit
step
sequenti
convers
inhibit
hivrt
equipot
azttp
preferenti
incorpor
elong
viral
dna
termin
dna
synthesi
incorpor
site
also
inhibit
polymeras
g
ono
et
al
similar
azt
enter
cell
nonfacilit
diffus
august
et
al
show
lesser
toxic
human
hematopoiet
progenitor
cell
compar
azt
mansuri
et
al
also
phosphoryl
azt
fiau
howev
azt
phosphoryl
much
lower
rate
wherea
fiau
arat
better
substrat
munchpetersen
et
al
et
al
johansson
et
al
sale
et
al
dfdc
arac
also
substrat
lower
affin
dck
recent
md
link
mutat
dgk
mutat
associ
myopath
form
mutat
dgk
hepatoencephalopath
form
md
associ
mtdna
deplet
mutat
dgk
confirm
salvag
pathway
enzym
involv
mainten
balanc
mitochondri
dntp
pool
mutat
gene
certainli
associ
variabl
phenotyp
howev
low
frequenc
suggest
dgk
gene
respons
mtdna
deplet
muscl
liver
respect
salviati
et
al
fiau
antivir
agent
potent
activ
hbv
replic
vitro
vivo
phase
ii
studi
patient
experienc
sever
toxic
due
drug
week
treatment
advers
effect
includ
nausea
vomit
pain
paraesthesia
subsequ
hepat
failur
pancreat
neuropathi
myopathi
lactic
acidosi
develop
probabl
due
multisystem
mitochondri
toxic
mckenzi
et
al
honkoop
et
al
possibl
mechan
fiau
toxic
includ
mitochondri
injuri
pyruv
oxid
inhibit
inde
fiautp
effici
incorpor
dna
polymeras
g
chain
elong
impair
possibl
lead
increas
inhibitori
effect
drug
site
replic
johnson
et
al
recent
novel
ribofuranosylnucleosid
e
uridin
oacylalkylsubstitut
arabinosyl
nucleosid
oacylbvarau
oacylarat
emerg
potent
select
competit
inhibitor
balzarini
et
al
recent
novel
class
potent
highli
specif
trityl
z
thymin
e
z
uracil
discov
balzarini
et
al
inhibitor
great
valu
enlighten
role
mitochondri
homeostasi
might
becom
practic
use
ad
concentr
partial
block
combin
antivir
anticanc
analogu
display
toxic
side
effect
due
activ
mitochondri
environ
ribonucleosid
analogu
far
investig
detail
adenosin
divers
effect
cardiovascular
nerv
respiratori
immun
system
fox
kelley
manfredi
holm
inhibitor
adk
play
import
pharmacolog
role
increas
extracellular
adenosin
concentr
cronstein
firestein
et
al
exampl
adk
inhibitor
kowaluk
et
al
recent
mani
promis
new
compound
like
jarvi
et
al
siegmund
et
al
varieti
pyrrolo
pyrimidin
na
ugarkar
et
al
synthes
test
adk
exhibit
rel
broad
substrat
specif
toler
modif
sugar
base
moieti
miller
et
al
accordingli
certain
nucleosid
antivir
anticanc
drug
substrat
adk
consequ
undergo
rapid
phosphoryl
vivo
monophosph
mani
case
monophosph
subsequ
convert
kinas
triphosph
function
activ
metabolit
exampl
includ
antivir
drug
ribavirin
willi
et
al
immunosuppress
drug
mizoribin
yamada
et
al
ribonucleosid
analogu
ribavirin
demonstr
activ
antirna
viru
compound
loeb
et
al
crotti
et
al
mechan
action
ribavirin
recent
demonstr
error
catastroph
induc
mutagen
incorpor
ribavirin
triphosph
rna
genom
hiv
viru
loeb
mullin
whether
rnk
may
tool
increas
activ
ribonucleosid
analogu
virusinfect
cell
therebi
suppress
develop
resist
viru
investig
recent
identifi
uck
phosphoryl
therebi
pharmacolog
activ
sever
cytotox
pyrimidin
ribonucleosid
analogu
may
pharmacolog
use
chemotherapi
cancer
phosphoryl
sever
test
cytidin
uridin
na
sever
pyrimidin
ribonucleosid
analogu
like
pasternak
et
al
vese
cihak
cihak
broucek
vese
cihak
smith
visser
lindsay
yu
exert
pharmacolog
effect
monophosph
form
inhibit
omp
decarboxylas
addit
incorpor
rna
dna
anderson
differ
mode
action
ribonucleosid
analogu
make
group
compound
interest
studi
develop
clinic
use
drug
promis
result
anim
tumor
model
recent
shown
cytosin
uracil
takatori
et
al
cyclopentenyl
cytosin
anoth
interest
compound
antitumor
activ
present
evalu
clinic
trial
verschuur
et
al
overexpress
human
fusion
gfp
chines
hamster
ovari
cho
cell
line
increas
sensit
certain
pyrimidin
ribonucleosid
analogu
van
rompay
express
increas
sensit
overexpress
result
increas
sensit
small
increas
differ
cytotox
base
analogu
observ
uckoverexpress
cell
compar
parent
cancer
cell
line
agreement
recent
literatur
mascia
ipata
clone
recombin
express
character
nucleosid
nucleotid
kinas
allow
pathway
nucleosid
na
metabol
outlin
detail
knowledg
metabol
pathway
import
develop
novel
antivir
anticanc
ribonucleosid
deoxyribonucleosid
analogu
character
pharmacolog
activ
differ
tissu
mammalian
cell
dna
replic
nucleu
mitochondria
enzym
respons
synthesi
deoxyribonucleotid
locat
cytosol
nucleu
mitochondria
cytosol
nucleu
separ
nuclear
membran
allow
diffus
small
protein
nucleotid
deoxyribonucleotid
pool
nucleu
cytosol
therebi
metabol
relat
equilibr
deoxyribonucleotid
pool
mitochondria
structur
separ
pool
cytosol
mitochondri
membran
mitochondrion
contain
inner
outer
membran
outer
membran
permeabl
small
molecul
kda
wherea
inner
membran
almost
imperm
passag
ion
molecul
physiolog
condit
howev
nucleosid
enter
mitochondria
membran
transport
protein
mitochondri
dnk
dgk
phosphoryl
deoxyribonucleosid
requir
dna
synthesi
mitochondria
addit
first
phosphoryl
step
also
mitochondri
ndpk
identifi
third
phosphoryl
step
question
remain
second
phosphoryl
step
littl
known
mitochondri
nmpk
two
mitochondri
ak
demonstr
may
respons
damp
phosphoryl
enzym
phosphoryl
dcmp
dgmp
dtmp
within
mitochondria
remain
identifi
sever
clinic
use
na
caus
sever
side
effect
mitochondri
toxic
import
identifi
character
mitochondri
enzym
may
contribut
toxic
interest
futur
studi
focu
identif
use
ribonucleosid
analogu
induc
mutat
rna
virus
hiv
hepat
c
viru
hcv
sever
acut
respiratori
syndrom
sar
loeb
et
al
crotti
et
al
cinatl
et
al
nie
et
al
ribonucleosid
analogu
ribavirin
demonstr
activ
antirna
viru
compound
crotti
et
al
loeb
mullin
nie
et
al
rna
viral
diseas
respons
major
viral
morbid
mortal
viral
diseas
includ
measl
polio
influenza
aid
hepat
c
idea
rna
na
administ
infect
cell
analogu
incorpor
polymeras
rna
copi
genom
nucleic
acid
encod
viru
subsequ
copi
incorpor
analogu
caus
increas
mutat
rate
viru
time
result
reduc
viabil
progeni
gener
viru
therebi
inhibit
viral
replic
investig
recent
clone
rnk
consid
ratelimit
step
next
phosphoryl
step
nmpk
ndpk
cellular
viral
rna
polymeras
contribut
develop
better
rna
incorpor
ribonucleosid
ribonucleotid
analogu
purin
ribonucleosid
analogu
also
investig
possibl
rna
viru
inhibitor
